

## ***DRAFT LIST OF AGENDA ITEMS***

### **Meeting of the Immunization Strategic Advisory Group of Experts 8-10 November 2011, Geneva**

**Please note that some of the agenda items are tentative only pending ability to prepare satisfactorily for review of evidence and issues to lead to successful discussions. Some issues may have to be deferred to the April 2012 SAGE meeting. A decision will be taken early September and a timed and more detailed agenda then provided.**

#### **Running items**

- ⇒ **Progress report from IVB Director For information and discussion**  
Includes information on status of implementation of recommendations, update on preparation of key topics on the horizon, and overview of regional hot topics (please note that for this meeting we plan to pilot integration of direct regional input in specific sessions and stop the stand alone regional priorities session. Feed-back on major regional priorities, challenges and hot topics will be collected from all six regions and reflected in this Director's report)
- ⇒ **Report from GAVI secretariat For information**
- ⇒ **Reports from other Advisory Committees For information and discussion**
  - Report of June 2011 GACVS meeting
  - Report of the September 2011 IPAC meeting
  - Report of the October 2011 ECBS meeting
  - Report of the October 2011 QUIVER meeting

#### **Specific topics**

- ⇒ **Decade of Vaccine/Delivery Framework For discussion**
- ⇒ **Reinforcing surveillance For information and discussion**  
The specific purpose of this session would be to appraise SAGE the proposed plan and scope of work for surveillance for vaccine preventable diseases, the progress and challenges with respect to strengthening surveillance and establishing surveillance networks that can help gather information for policy making and to monitor the impact of vaccines. This would particularly highlight the challenges of establishing sentinel sites for invasive bacterial diseases, limits of integration of surveillance, challenges

to secure funding and country ownership. This would allow a discussion and insight into the balance between promoting routine surveillance at country level versus focusing on a fewer number of specialized sentinel sites that will generate reliable data and highlight the need for adequate and sustained investments both from national governments and donor agencies to support surveillance. The aim is to discuss a way forward to overcome challenges

### **Validation of coverage figures For discussion**

The specific purpose of this session would be review the best estimate approach to review the vaccine coverage at country level and to also discuss methods to validate coverage figures at country level, the two being closely linked. This would entail a review of situation and agreement on methodologies and way forward.

### ⇒ **Polio eradication For discussion**

#### **Use of bOPV in pre eradication (tentative)**

SAGE expanded the IPV working group's remit to ask it to assess whether, in view of the apparent eradication of type-2 wild poliovirus and the preponderance of circulating type-2 vaccine-derived polioviruses in recent years, trivalent OPV should be replaced with bivalent OPV for routine vaccination. SAGE requested that the working group report on this by November 2011.

#### **Monitoring of progress**

### ⇒ **TB vaccines For information and discussion**

(a) an update on the state and the issues/bottlenecks of TB vaccine development

(b) guidance from SAGE on target product profile (TPP) of a new TB vaccine, in particular infant vs adolescent/adult.

### ⇒ **Use of influenza vaccines with main focus on seasonal flu For decision (tentative)**

The purpose is to review and update the recommendations on the use of seasonal influenza vaccines with a view to update the 2005 vaccine position paper. It is hoped that the final discussion by SAGE will take place in November 2011. A SAGE WG has been established for this purpose and proposed approach was already discussed and agreed by SAGE at the November 2010 meeting.

### ⇒ **Conjugate pneumococcal vaccines: serotype replacement, consensus building. For decision**

As stated in the report of the November 2010 SAGE meeting, the results of a systematic review of published and unpublished data on serotype

replacement will be presented to SAGE in November 2011. In addition to summarizing available information on the key determinants of prevalence and changes of pneumococcal serotypes and the occurrence and magnitude of serotype replacement following use of PCV, the analysis will also propose guidelines for the collection, analysis and interpretation of surveillance data to monitor serotype replacement with the newer PCV formulations. This would be closely related to discussions on optimizing the immunization schedule

⇒ **Optimizing immunization schedules for conjugate pneumococcal vaccines For decision**

The above two specific pneumococcal related discussions will likely result in an updating of the pneumococcal vaccine position paper and consolidation of the currently separate papers dealing with polysaccharide and conjugate vaccines in one and only position paper.

⇒ **Hepatitis A For decision**

The purpose is to review and update the recommendations on the use of seasonal hepatitis A vaccines with a view to update the 2000 vaccine position paper.